Regulatory inspectors from the FDA and EMA frequently evaluate a firm’s fundamental understanding of container closure physics during audits. Referencing PDA TR 27 in validation master plans (VMPs) and justification protocols demonstrates a deep, historical understanding of packaging science. It provides the foundational logic required to build a robust CCIT strategy, ensuring that sterile drugs reach patients without compromised sterility or altered chemical efficacy.
: Under the intense scrutiny of the leak detector, a tiny spike appeared. It wasn't the glass at all—it was a microscopic defect in the aluminum crimp of the stopper, a flaw so small it was invisible to the human eye but large enough to allow microbial ingress over time. Validation of the Cure pda technical report 27 pdf
(A method for packages sealed under vacuum) Regulatory inspectors from the FDA and EMA frequently
: The full digital or paper version can be purchased at the PDA Bookstore . : Under the intense scrutiny of the leak
It offers technical specifics on how to set up sensitivity limits for various container types, such as vials, syringes, and ampoules.
Historically, the industry relied heavily on traditional sterility tests to prove that a product was safe. However, regulatory bodies like the US FDA recognized that sterility tests could only detect contamination that had already occurred, and might miss micro-leaks that could compromise a product over time.